Page 122 - 2022-06-中国全科医学

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·759·

versus teriparatide in glucocorticoid-induced osteoporosis patients 2395. DOI：10.1002/ART.30385.
with prior bisphosphonate treatment［J］. Bone Rep，2020，13： ［28］IOLASCON G，MORETTI A，TORO G，et al. Pharmacological
100293. DOI：10.1016/j.bonr.2020.100293. therapy of osteoporosis：what's new?［J］. Clin Interv Aging，
［15］SAAG K G，WAGMAN R B，GEUSENS P，et al. Denosumab 2020，15：485-491. DOI：10.2147/CIA.S242038.
versus risedronate in glucocorticoid-induced osteoporosis：a ［29］MARKHAM A. Romosozumab：first global approval［J］. Drugs，
multicentre，randomised，double-blind，active-controlled， 2019，79（4）：471-476. DOI：10.1007/s40265-019-01072-6.
double-dummy，non-inferiority study［J］. Lancet Diabetes ［30］DAVIS K，DAVENPORT K，SCHOTS L. FDA Approves
Endocrinol，2018，6（6）：445-454. DOI：10.1016/S2213-8587 EVENITYTM（romosozumab-aqqg） for the treatment of
（18）30075-5. osteoporosis in postmenopausal women at high risk for fracture［EB/
［16］SAAG K G，PANNACCIULLI N，GEUSENS P，et al. Denosumab OL］. ［2021-07-20］. https：//www.multivu.com/players/
versus risedronate in glucocorticoid-induced osteoporosis：final English/8490251-amgen-evenity-postmenopausal-osteoporosis/.
results of a twenty-four-month randomized，double-blind， ［31］JASCHKE N，HOFBAUER L C，GÖBEL A，et al. Evolving
double-dummy trial［J］. Arthritis Rheumatol，2019，71（7）： functions of Dickkopf-1 in cancer and immunity［J］. Cancer
1174-1184. DOI：10.1002/art.40874. Lett，2020，482：1-7. DOI：10.1016/J.CANLET.2020.03.031.
［17］MATSUNO H. Assessment of distal radius bone mineral density in ［32］RACHNER T D，GOBEL A，BENAD-MEHNER P，et al.
osteoporosis patients receiving denosumab，including those with Dickkopf-1 as a mediator and novel target in malignant bone
rheumatoid arthritis and those receiving oral glucocorticoids［J］. disease［J］. Cancer Lett，2014，346：172-177. DOI：
DRUGS R D，2016，16（4）：347-353. DOI：10.1007/S40268- 10.1016/j.canlet.2014.01.010.
016-0146-8. ［33］HEILAND G R，ZWERINA K，BAUM W，et al. Neutralisation
［18］YANBEIY Z A，HANSEN K E. Denosumab in the treatment of of DKK-1 protects from systemic bone loss during inflammation and
glucocorticoid-induced osteoporosis：a systematic review and meta- reduces sclerostin expression［J］. Ann Rheum Dis，2010，69（12）：
analysis［J］. Drug Des Devel Ther，2019，13：2843-2852. 2152-2159. DOI：10.1136/ard.2010.132852.
DOI：10.2147/DDDT.S148654. ［34］TAI N，INOUE D. Anti-Dickkopf1（DKK1） antibody as a
［19］RAUNER M，TAIPALEENMÄKI H，TSOURDI E，et al. bone anabolic agent for the treatment of osteoporosis［J］. Clin
Osteoporosis treatment with anti-sclerostin antibodies-mechanisms Calcium，2014，24（1）：75-83.
of action and clinical application［J］. J Clin Med，2021，10（4）： ［35］GLANTSCHNIG H，SCOTT K，HAMPTON R，et al. A rate-
787. DOI：10.3390/jcm10040787. limiting role for Dickkopf-1 in bone formation and the remediation
［20］孟迅吾，周学瀛 . 协和代谢性骨病学［M］. 北京：中国协和医 of bone loss in mouse and primate models of postmenopausal
科大学出版社，2021：542-557. osteoporosis by an experimental therapeutic antibody［J］. J
［21］WIJENAYAKA A R，KOGAWA M，LIM H P，et al. Sclerostin Pharmacol Exp Ther，2011，338（2）：568-578. DOI：
stimulates osteocyte support of osteoclast activity by a RANKL- 10.1124/jpet.111.181404.
dependent pathway［J］. PLoS One，2011，6（10）：e25900. ［36］LIU M，KURIMOTO P，ZHANG J，et al. Sclerostin and DKK1
DOI：10.1371/journal.pone.0025900. inhibition preserves and augments alveolar bone volume and
［22］VAN LIEROP A H，APPELMAN-DIJKSTRA N M， architecture in rats with alveolar bone loss［J］. J Dent Res，
PAPAPOULOS S E. Sclerostin deficiency in humans［J］. Bone， 2018，97（9）：1031-1038. DOI：10.1177/0022034518766874.
2017，96：51-62. DOI：10.1016/J.BONE.2016.10.010. ［37］FLORIO M，GUNASEKARAN K，STOLINA M，et al. A bispecific
［23］VAN LIEROP A H，HAMDY N A，PAPAPOULOS S E. antibody targeting sclerostin and DKK-1 promotes bone mass accrual
Glucocorticoids are not always deleterious for bone［J］. J and fracture repair［J］. Nat Commun，2016，7：11505. DOI：
Bone Miner Res，2010，25（12）：2796-2800. DOI： 10.1038/ncomms11505.
10.1002/JBMR.151. ［38］IYER S P，BECK J T，STEWART A K，et al. A Phase Ⅰ B
［24］SATO A Y，CREGOR M，DELGADO-CALLE J，et al. Protection multicentre dose-determination study of BHQ880 in combination
from glucocorticoid-induced osteoporosis by anti-catabolic signaling with anti-myeloma therapy and zoledronic acid in patients with
in the absence of sost/sclerostin［J］. J Bone Miner Res，2016，31 relapsed or refractory multiple myeloma and prior skeletal-related
（10）：1791-1802. DOI：10.1002/JBMR.2869. events［J］. Br J Haematol，2014，167（3）：366-375. DOI：
［25］YAO W，DAI W，JIANG L，et al. Sclerostin-antibody treatment 10.1111/bjh.13056.
of glucocorticoid-induced osteoporosis maintained bone mass and ［39］KATO T，KHANH V C，SATO K，et al. Elevated expression
strength［J］. Osteoporos Int，2016，27（1）：283-294. DOI： of DKK-1 by glucocorticoid treatment impairs bone regenerative
10.1007/S00198-015-3308-6. capacity of adipose tissue-derived mesenchymal stem
［26］ACHIOU Z，TOUMI H，TOUVIER J，et al. Sclerostin antibody cells［J］. Stem Cells Dev，2018，27（2）：85-99. DOI：
and interval treadmill training effects in a rodent model of 10.1089/scd.2017.0199.
glucocorticoid-induced osteopenia［J］. Bone，2015，81：691- ［40］COLDITZ J，THIELE S，BASCHANT U，et al. Osteogenic DKK1
701. DOI：10.1016/J.BONE.2015.09.010. mediates glucocorticoid-induced but not arthritis-induced bone
［27］MARENZANA M，GREENSLADE K，EDDLESTON A， loss［J］. J Bone Miner Res，2019，34（7）：1314-1323.
et al. Sclerostin antibody treatment enhances bone strength but DOI：10.1002/JBMR.3702.
does not prevent growth retardation in young mice treated with （收稿日期：2021-08-04；修回日期：2021-09-22）
dexamethasone［J］. Arthritis Rheum，2011，63（8）：2385- （本文编辑：毛亚敏）